DNA METHYLATION Eligibility Fecal microbiota Gene expression Epigénétiques Ustekinumab Epigenetics Colorectal cancer Algorithm Inflammatory bowel diseases IBD COLON-CANCER DNA methylation Crohn’s disease CARCINOGENESIS Clinical guidelines Tailored therapy Colectomy Genes Disability Inflammatory Bowel Diseases Disease Progression Colon cancer Dysbiosis Survival Inflammatory bowel disease MARKER Microbiote Resistance Dysbiose Over 80s Disease progression Immune cells Crohn's disease T1118 translocation Screening MALT Contraindication IL12 Eradication Effectiveness Anti-TNF Patient-reported outcome IL23 MICROBIOTA Upper gastrointestinal tract Colonic epithelial primary cells Acceptability Small molecules Therapeutics Ulcerative colitis Inclusion Alkylating agents RISK Immunosuppressant HIV Biologics 18 FDG-PET/CT Parvimonas micra Inhibitor Surgery Colon Microbiota Safety Original Article Clinical Gene methylation Maintenance therapy Cost effectiveness Helicobacter pylori Methylation Thérapie ciblée Bacteria Gènes Stricture Rituximab plus chlorambucil Venous thromboembolism Kidney diseases Consensus Rituximab Cell adhesion Neoadjuvant chemotherapy Cancer MORTALITY Clinical trial Bactéries Anti-TNF agents Résistance Primary sclerosing cholangitis Vedolizumab Monitoring Colorectal cancer Colibactin and lipids Biomarker Tuberculosis PCR Intestinal crypts Patients experience Heart disease risk factors Drug Méthylation Endoscopic treatment